The proposed phase 2a trial will determine whether MIB-626 treatment in adults with COVID-19
infection and stage 1 acute kidney injury is more efficacious than placebo in preventing
worsening of kidney function, as assessed by longitudinal changes in serum creatinine
concentration, and in attenuating the inflammatory response to the infection.